Kardigan ^{Priced, Nasdaq: KARD}

Kardigan is a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Our mission is to develop multiple targeted cardiovascular treatments in parallel that bring people with cardiovascular diseases closer to the cures they deserve. We leverage deep domain expertise in cardiovascular biology, patient data, and advanced analytics to accelerate drug discovery and development, aiming to deliver impactful therapies efficiently and at scale. We are advancing three late-stage cardiovascular therapies in indications for which no approved therapies currently exist: 1) Danicamtiv. An investigational oral cardiac atrial and ventricular myosin activator for the treatment of genetic dilated cardiomyopathy (“DCM”) caused by pathogenic variants in myosin heavy chain 7 (“MYH7”) and titin (“TTN”). 2) Ataciguat. An investigational oral, once-daily soluble guanylate cyclase (“sGC”) activator aimed at slowing the progression of calcific aortic valve stenosis (“CAVS”) in patients with moderate disease. 3) Tonlamarsen. An investigational liver-directed antisense oligonucleotide (“ASO”) administered once-monthly via subcutaneous injection, targeting hepatic angiotensinogen (“AGT”) for the management of blood pressure in acute severe hypertension (“ASH”) post-hospitalization.